Figure 1. BCR-ABL Mutagenesis and In Vitro Screen for STI-571 Resistance
The 10 kb plasmid pEYKBA was propagated in XL-1 red (Stratagene), which introduces random point mutations at a rate of one base pair substitution per 10 kb replicated DNA. Retroviral supernatants with titers of 10 6 would represent a library approximating saturation mutagenesis of BCR-ABL. Cells were selected in either 5 or 10 M STI-571, as the numbers of colonies resulting from exposure to lower drug concentrations (1 and 2 M) were too numerous to analyze and did not afford tight selection of resistant variants.
tients, and predicts a number of additional variants that sequenced the recovered genes to identify mutations ( Figure 1 ). are likely to be clinically problematic. Furthermore, we have discovered novel variants that illuminate an imporFrom 283 drug-resistant colonies, we identified 112 distinct amino acid substitutions affecting 90 residues. tant functional principle: while STI-571 binds preferentially to the inactive conformation of the ABL kinase, Substitutions at 68% of positions were identified more than once. Figure 2 depicts a sequence alignment of drug-resistant mutations can shift the equilibrium in the opposite direction, further destabilizing and activating ABL with the closely related cytoplasmic tyrosine kinases SRC and HCK as well as the receptor kinases KIT the kinase, and rendering the inactive conformation less accessible for drug binding. Our screen is a paradigm and platelet-derived growth factor receptor (PDGF-R), both of which are also targets of STI-571. The variants for discovery of drug-resistance mechanisms for a growing list of target-directed anti-cancer agents. recovered in the screen are indicated, as are the salient secondary structural motifs and functional domains of ABL. To verify the activity of variants in isolation (since Results some recovered viruses carried two or more mutations) we generated 65 variants by site-directed mutagenesis An In Vitro Screen for Drug-Resistant Variants We constructed pEYKBA by introducing the full-length of the native BCR-ABL sequence. We reintroduced these into BaF3 cells, and measured cell viability in in-BCR-ABL cDNA into pEYK3.1, a retroviral vector designed to facilitate expression screens by allowing direct creasing doses of drug to document the concentration that provided half-maximal inhibition of cell viability recovery of integrated proviruses from genomic DNA of infected cells (Koh et al., 2002). We randomly mutagen-(IC50 ; Tables 1 and 2) . We also performed phosphotyrosine immunoblot analysis on protein lysates of BaF3 ized the BCR-ABL plasmid by propagation in a bacterial strain that is deficient in three major pathways for DNA cells incubated with increasing doses of STI-571 ( Figure  3 ). The vast majority of the variants we regenerated by repair (XL-1 red; Stratagene). We transfected the mutant plasmids onto 293T cells, recovered retroviral supernasite-directed mutagenesis showed enhanced cell growth (elevated IC50) and persistent autophosphorylation in tants, transduced the transformation-susceptible interleukin 3-dependent hematopoietic cell line BaF3 (Dathe presence of STI-571 and, thus, were confirmed to be drug resistant (59 of 65; 91%). We failed to replicate ley and Baltimore, 1988), and selected for colony growth in soft agar in the absence of IL-3 and the presence drug resistance for six variants, establishing a modest 9% false positive rate for the screen. of either 5 or 10 M STI-571. Under these conditions, colonies arise only from cells carrying BCR-ABL cDNAs
In this manuscript, we number the amino acid residues in our figures according to the human c-Abl type Ib that express transformation-competent and drug-resistant variants. After 10 days, we plucked well-separated sequence, rather than type Ia, which was the custom arbitrarily adopted by Kuriyan and colleagues in the origindividual colonies, which varied in size, and expanded them in liquid culture. We then isolated genomic DNA inal report of the ABL kinase domain structure (Schindler et al., 2000) . Type Ia numbering has been perpetuated and recovered the integrated provirus by direct rescue, as described (Koh et al., 2002), or amplified specific in recent reports describing drug-resistant mutations arising in patients. However, type Ib is the major form regions of the ABL gene sequence by PCR. We then The variants V275A and M337A generated by site-directed mutagenesis did not specify drug-resistant autophosphorylation. Certain variants recovered in the screen also did not generate drug-resistant autophosphorylation levels significantly greater than native Bcr-Abl (V224E, A385D, G482D) and thus were judged to be false positives. Numbering of residues according to type Ia c-Abl is shown in parentheses for substitutions previously linked to drug resistance in patients.
of c-Abl expressed in cells, and the description of its adoption of the type Ib numbering system in this and future publications. In Tables 1, 2, When expressed in BaF3 cells, the STI-571-resistant Q319H variant has elevated baseline levels of tyrosine isolated each of these major patient variants in our screen, as well as additional residues mapping within autophosphorylation, which is evident even though BcrAbl already shows markedly elevated levels of autothese same functional motifs, suggesting that our screen was more comprehensive than the compiled data phosphorylation relative to c-Abl ( Figure 3B ). Mutation in these residues implies that alteration of SH3 association from analysis of clinical samples (Table 1) ably contact SH3 and the SH2-CD linker, respectively, were also shown to destabilize the c-Abl kinase (Barila The structure of the N-terminal cap region of ABL is unknown and, thus, is not depicted in Figure 4. and Superti-Furga, 1998). Again, our study links amino acid substitutions at these two residues to drug resistance. Thus, our random, unbiased screen for drug resisVariants Affecting the SH3-Kinase tance identifies many of the same residues that have Domain Interaction been implicated by site-directed mutagenesis in the The SRC family of kinases is maintained in an assemmaintenance of ABL in an assembled and presumably bled, autoinhibited conformation in part by intramolecuautoinhibited conformation, suggesting that allosteric lar interactions between the SH3 domain, the SH2-CD regulation of kinase activity is intimately tied to drug linker, and the catalytic domain (Xu et al., 1999). Eviresistance. dence from site-directed mutagenesis suggests that the ABL kinase is regulated by a similar set of interactions, as mutants in each of these three domains activate c-Abl A Model of Autoinhibited ABL Prior to the report by Kuriyan and colleagues in this kinase activity and transforming function (Barila and Superti-Furga, 1998). The SH2-CD linkers of SRC and ABL issue of Cell (Nagar et al., 2003), the combined SH3/SH2 and kinase regions of c-Abl had yet to be crystallized as are poorly conserved except for a lysine-proline motif known to interact with SH3 in SRC. It has been shown a unit, and the structure of the SH2-CD-linker domain of ABL had not been defined. However, given the strong previously that mutation of the KP residues (K241E/ P242G) or mutation of two prolines within the ABL SH2-homologies between ABL and SRC, whose crystal structure is known, and our evidence that drug-resistant mu-CD linker (P242E/P249E) activates autophosphorylation and transformation (Barila and Superti-Furga, 1998). Our tations in ABL involve residues homologous to ones that make critical interdomain contacts in SRC, we built a screen for drug resistance recovered a remarkably similar set of mutations, including the T243A variant, which model for the presumptive autoinhibited form of ABL ( Figure 4B ). Treating the crystal structures of the ABL is immediately adjacent to P242, and a substitution at position P249. As discussed above, mutation of the ki-SH3, SH2, and kinase regions as isolated domains, we aligned the domains relative to one another so that munase domain residues K313 and Q319, which presum-tated residues in ABL coincided with their homologous Table 3 . Mutations in STI571 Contact Sites residues in SRC. The backbone trace of the presumptive ABL model was easily aligned to the fully-assembled SRC structure without any major inconsistencies or disruptions ( Figure 4C ). In our model, Y89 contacts the linker residue K238, while linker position T243 packs against Q319, exemplifying the linker's role in bridging the gap between SH3 and the kinase domain ( Figure  4B, right) . Mutation of each of these residues confers drug resistance (N.B., variants Y89D/H/N, K238E, T243A, Q319H; Table 1 and Table 2 ), suggesting that these complementary contacts are critical for maintaining the assembled conformation of ABL. Some of the residues highlighted red in Figure 4A as presumptive contacts with the SH3 and SH2 domains are hidden in the reassembled molecules (e.g., L320, Q365; Figure  4B ). Other residues that are not visible on the surface projections may be involved in positioning residues that do directly contact these domains.
Given the relative ease with which our assembled ABL model conforms to the known crystal structure of SRC, we conclude that the ABL kinase must be maintained . Variants in contact residues Y272 (Y253-tance mutations missed by our sequencing efforts. Curiously, however, though failing to manifest enhanced Ia), T334 (T315-Ia), and F336 (F317-Ia) have been described in patients and in our screen, while our screen drug resistance, some of these mutants show persistent levels of tyrosine autophosphorylation at high doses of revealed multiple additional variants in contact residues (L267R/V, A288V, M309L/T, G340W, and I379F). In order STI-571 (e.g., S176T, A236G; Figure 3A ). This biochemical resistance suggests these might be weak cooperatto understand why some residues known to contact the drug remained invariant in our screen, we performed ing mutations whose modest effects might not be resolved in short-term cell proliferation assays. We site-directed mutagenesis and measured the effects on kinase activity and drug resistance (Table 3) . Contact acknowledge that many of the mutations identified herein may never be seen in patients but be peculiar to residue variants V275A and M337A were active kinases, but their STI-571 resistance profile was indistinguishour screen, since transformation of BaF3 cells is more permissive than leukemia induction, and the majority of able from native Bcr-Abl ( Figure 3B ). The peptide backbone and not the amino acid side chain of M337 medinovel mutations exert modest effects on drug resistance. Finally, while our screen was exhaustive, it was ates the drug contact for this residue, which explains why amino acid substitution might not negatively affect not complete. We could productively sequence more clones to detect additional mutations within the reguladrug binding. Mutation of I332, F401, and the highly conserved ion pair K290 and E305 resulted in inactive tory domains and extend our survey to include the large C-terminal domain of ABL as well as BCR sequences. kinases (Table III; We have performed an in vitro screen of mutagenized BCR-ABL to identify amino acid substitutions that conMutations Predicted to Be Clinically Problematic fer resistance to STI-571. Our results reveal a more comAs determined in cell-based assays, the IC50 for the prehensive catalog of potential drug-resistant mutations mutants correlates roughly with the frequency of recovthan provided by clinical surveys to date and illuminate ery in our screen (Table 1 ). The robust P loop variants novel mechanisms by which alterations in the ABL strucare detected most frequently, a correlation also noted in ture thwart drug efficacy. In addition to all major mutaclinical populations (Branford et al., 2002) . As discussed tions detected in patients, we identified novel substituabove, variants at L267 (L248-Ia) are certain to be found tions of residues within and beyond the kinase domain in relapsed or refractory CML patients. No mutants in that influence the conformational state of the kinase and the catalytic ␣ helix have been reported to date from confer drug resistance through allosteric mechanisms. patients, but given their significant degree of drug resisAn important principle to emerge from our in vitro screen tance, such mutations will likely be discovered when and subsequent structural modeling is that numerous additional patients are surveyed (e.g., E298K, E300K). drug-resistant variants destabilize an autoinhibited conWe predict that P249L, L403M, E469K, F505S, and formation of the ABL kinase to which STI-571 preferen-E518K/I are also likely to be clinically problematic. Mutatially binds, shifting the equilibrium toward the active tions in the SH3 domain and S206F/P in SH2 generate kinase conformation that precludes drug binding. Our only low-level drug resistance (IC50 ‫1ف‬ M). Escalating results lend support to the hypothesis that ABL is subthe treatment dose of STI-571 should be sufficient to ject to a similar mechanism of autoinhibition as c-SRC suppress these variants, suggesting that these may be (Barila and Superti (Table 1) . We have not recovered E374G (E355G-Ia), F401L (F382L-Ia), and L406M covered in our screen while also raising important questions for the future. Though the reported structure (L387M-Ia). These first two examples were discovered in patients as a second site mutation together with a cannot resolve the contact sites of the cap peptide as it courses over the SH3 and SH2 domains, we have mutation known to confer resistance and have not yet been observed in isolation (Shah et al., 2002) . In our isolated drug-resistant mutants along this stretch, particularly at residue K70, that imply the importance of hands, the F401A (F382-Ia) mutation produces an inactive kinase, likely by disrupting the Mg 2ϩ binding triad such contacts and beg for further structure refinement. Molecular dynamic studies of ABL suggest that the con- (Table 3) .g., S167C, S176T, V224E, A236G, A385D, and G482D) .
tor residues between SH3 and SH2 activates c-Abl ki- 
